Latest News and Press Releases

BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...

Clear recognition of high unmet need and urgency for the SCN2A community and plausibility of the mechanism of elsunersen  FDA agreed to proposed changes to the EMBRAVE3 trial design to be a...

Dublin, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The "Refractory Epilepsy Treatment Market - A Global and Regional Analysis: Focus on Treatment Type, Patient Type, Seizure Type, Distribution Channel, and...

Positive Results in the EMBOLD study of relutrigine showed a 53% placebo-adjusted reduction in seizures (p < 0.0002), 66% increase in motor seizure-free days (p = 0.0340), broad and clinically...

Successful interim analysis triggered early stop for efficacy Topline study results to be shared at the American Epilepsy Society Annual Meeting on December 6, 2025 Praxis confirms an upcoming...

Fort Myers, Fla., Dec. 04, 2025 (GLOBE NEWSWIRE) -- From viral neuroscience videos to consulting with patients nationwide, Dr. Jessica Lowe, widely known as “Doctor Brain Barbie” (Instagram/TikTok:...

NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need,...

Positive topline results announced from Phase 2a clinical trial of RAP-219 in patients with focal onset seizures Phase 2 trial of RAP-219 in bipolar mania enrolling patients and on track, with topline...

MIAMI, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...

Comprehensive meeting with FDA conducted in Q3 in conjunction with Breakthrough Therapy Designation Key aspects of a potential NDA application discussed and aligned with the Agency Praxis plans to...